Comparison of Overall Survival on Surgical Resection Versus Transarterial Chemoembolization with or Without Radiofrequency Ablation in Intermediate Stage Hepatocellular Carcinoma: a Propensity Score Matching Analysis

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2020 Apr 11

PMID 32272898

Citations 20

Authors

Chih-Wen Lin

Yaw-Sen Chen

Gin-Ho Lo

Yao-Chun Hsu

Chia-Chang Hsu

Tsung-Chin Wu

Jen-Hao Yeh

Pojen Hsiao

Pei-Min Hsieh

Hung-Yu Lin

Chih-Wen Shu

Chao-Ming Hung

Affiliations

Soon will be listed here.

Abstract

Background: Patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) are recommended to undergo transcatheter arterial chemoembolization (TACE). However, TACE in combination with radiofrequency ablation (RFA) is not inferior to surgical resection (SR), and the benefits of surgical resection (SR) for BCLC stage B HCC remain unclear. Hence, this study aims to compare the impact of SR, TACE+RFA, and TACE on analyzing overall survival (OS) in BCLC stage B HCC.

Methods: Overall, 428 HCC patients were included in BCLC stage B, and their clinical data and OS were recorded. OS was analyzed by the Kaplan-Meier method and Cox regression analysis.

Results: One hundred forty (32.7%) patients received SR, 57 (13.3%) received TACE+RFA, and 231 (53.9%) received TACE. The OS was significantly higher in the SR group than that in the TACE+RFA group [hazard ratio (HR): 1.78; 95% confidence incidence (CI): 1.15-2.75, p = 0.009]. The OS was significantly higher in the SR group than that in the TACE group (HR: 3.17; 95% CI: 2.31-4.36, p < 0.0001). Moreover, the OS was significantly higher in the TACE+RFA group than that in the TACE group (HR: 1.82; 95% CI: 1.21-2.74, p = 0.004). The cumulative OS rates at 1, 3 and 5 years in the SR, TACE+RFA, and TACE groups were 89.2, 69.4 and 61.2%, 86.0, 57.9 and 38.2%, and 69.5, 37.0 and 15.2%, respectively. After propensity score matching, the SR group still had a higher OS than those of the TACE+RFA and TACE groups. The TACE+RFA group had a higher OS than that of the TACE group.

Conclusion: The SR group had higher OS than the TACE+RFA and TACE groups in BCLC stage B HCC. Furthermore, the TACE+RFA group had higher OS than the TACE group.

Citing Articles

Surgical treatment strategies for multifocal hepatocellular carcinomas.

Jia X, Liao A, Jiang L Hepatobiliary Surg Nutr. 2024; 13(6):1071-1076.

PMID: 39669067 PMC: 11634419. DOI: 10.21037/hbsn-24-408.

A Decade of Experience Between Open and Minimally Invasive Hepatectomies for Hepatocellular Carcinoma.

Park A, Kwon Y, Savsani K, Sharma A, Sambommatsu Y, Imai D Medicina (Kaunas). 2024; 60(11).

PMID: 39596922 PMC: 11596858. DOI: 10.3390/medicina60111737.

Development and validation of a nomogram to predict cancer-specific survival of patients with large hepatocellular carcinoma accepting surgical resection: a real-world analysis based on the SEER database.

Li L, Liu C, Li H, Yang J, Pu M, Zhang S J Gastrointest Oncol. 2024; 15(4):1657-1673.

PMID: 39279946 PMC: 11399871. DOI: 10.21037/jgo-24-285.

The role of resection in hepatocellular carcinoma BCLC stage B: A multi-institutional patient-level meta-analysis and systematic review.

Lopez-Lopez V, Kalt F, Zhong J, Guidetti C, Magistri P, Di Benedetto F Langenbecks Arch Surg. 2024; 409(1):277.

PMID: 39269544 PMC: 11399194. DOI: 10.1007/s00423-024-03466-x.

Development of a Novel CD8 T Cell-Associated Signature for Prognostic Assessment in Hepatocellular Carcinoma.

Li X, Qu X, Li S, Lin K, Yao N, Wang N Cancer Control. 2024; 31:10732748241270583.

PMID: 39152700 PMC: 11331481. DOI: 10.1177/10732748241270583.

References

Liu Y, Xue D, Tan S, Zhang Q, Yang X, Li Y . Comparison of macrovascular invasion-free survival in early-intermediate hepatocellular carcinoma after different interventions: A propensity score-based analysis. J Cancer. 2019; 10(17):4063-4071. PMC: 6692624. DOI: 10.7150/jca.29850. View

Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H . Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatol Res. 2019; 49(8):919-928. DOI: 10.1111/hepr.13348. View

Guo H, Wu T, Lu Q, Li M, Guo J, Shen Y . Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages. Cancer Manag Res. 2018; 10:361-369. PMC: 5827460. DOI: 10.2147/CMAR.S152707. View

Omata M, Cheng A, Kokudo N, Kudo M, Lee J, Jia J . Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11(4):317-370. PMC: 5491694. DOI: 10.1007/s12072-017-9799-9. View

Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M . Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017; 67(2):302-309. DOI: 10.1016/j.jhep.2017.03.011. View

Yin L, Li H, Li A, Lau W, Pan Z, Lai E . Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014; 61(1):82-8. DOI: 10.1016/j.jhep.2014.03.012. View

Bholee A, Peng K, Zhou Z, Chen J, Xu L, Zhang Y . Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol. 2017; 19(7):844-852. DOI: 10.1007/s12094-016-1611-0. View

Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

Ho M, Hasegawa K, Chen X, Nagano H, Lee Y, Chau G . Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer. 2016; 5(4):245-256. PMC: 5075807. DOI: 10.1159/000449336. View

10.

Forner A, Gilabert M, Bruix J, Raoul J . Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014; 11(9):525-35. DOI: 10.1038/nrclinonc.2014.122. View

11.

Zhong J, Xiang B, Gong W, Ke Y, Mo Q, Ma L . Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One. 2013; 8(7):e68193. PMC: 3706592. DOI: 10.1371/journal.pone.0068193. View

12.

Bolondi L, Burroughs A, Dufour J, Galle P, Mazzaferro V, Piscaglia F . Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2013; 32(4):348-59. DOI: 10.1055/s-0032-1329906. View

13.

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

14.

Liu F, Chen M, Mei J, Xu L, Guo R, Lin X . Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. J Oncol. 2019; 2019:6298502. PMC: 6766138. DOI: 10.1155/2019/6298502. View